ASH 2023 | Quadruplet therapies for treating MM: the current evidence and the findings of a Phase II trial

Benjamin Derman, MD, University of Chicago, Chicago, IL, gives an overview of ongoing research into daratumumab-based quadruplet therapy to treat patients with newly diagnosed multiple myeloma (NDMM), including trials CASSIOPEIA (NCT02541383), GRIFFIN (NCT02874742), PERSEUS (NCT03710603), IsKia (NCT04483739), and GEM2017FIT (2017-000044-18). Dr Derman goes on to discuss the findings of the Phase II study (NCT01816971) with which he was involved, which investigated the safety and efficacy of 24 cycles of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in patients with NDMM, without autologous stem cell transplantation (autoSCT) and regardless of transplant eligibility. The study’s primary endpoint was met, with 75% of patients reaching stringent complete response (sCR) and/or MRD-negativity at the end of cycle 8. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.